http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102875573-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56f308054f2c2f9dae9b2a85126efab7 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-546 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D501-12 |
| filingDate | 2012-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b03c2004c09e4e3abda4403079011074 |
| publicationDate | 2013-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102875573-B |
| titleOfInvention | Cefixime compound and pharmaceutical composition thereof |
| abstract | The invention relates to a pharmaceutical compound and in particular relates to a cefixime crystal compound. The cefixime compound is a crystal, and an X-ray powder diffraction pattern obtained by Cu-Kalpha ray measurement is shown as a figure 1. Main granularity of the cefixime compound crystal disclosed by the invention is 45-80Mum, and the distribution width is 30-100Mum. The cefixime crystal disclosed by the invention has high stability and high purity and is applicable to preparation of the pharmaceutical compound, and preferable dosage forms are dispersible tablets and granules. |
| priorityDate | 2012-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.